報價延遲最少15分鐘:2025/05/14 00:43 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.4155 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.33/-0.50
|
|
企業價值
106.87M
|
| 資產負債 |
|
每股賬面淨值
0.26
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
28.70M
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/14 00:43 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |